NDAORALTABLET
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tolazamide is an oral sulfonylurea antidiabetic agent approved in 1984 for the treatment of type 2 diabetes mellitus. It works by stimulating insulin secretion from pancreatic beta cells to lower blood glucose levels. The drug is formulated as a tablet for oral administration.
LOE Approaching
As a legacy oral antidiabetic with approaching loss of exclusivity, this product likely operates within a mature, consolidated team focused on retention and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on tolazamide offers limited growth potential but provides stability in a managed-decline environment where value is driven by pricing, formulary access, and customer retention rather than innovation. Roles tend to be execution-focused and smaller in scale, suited to candidates seeking legacy product expertise or transitional assignments.
Brand ManagerSenior Field Sales Representative
Worked on TOLAZAMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.